v3.26.3
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Cash flow from operating activities:    
Net loss for the year $ (35,325,292) $ (26,556,140)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization 15,271 15,271
Financial income, net (14,804) (56,473)
Depreciation 104,064 91,356
Share-based compensation 1,735,389 776,879
Share of loss on equity investment 263,477 224,212
Change in fair value of warrants (298,733) (758,364)
Unrealized gain on BC Therapeutics investment (92,227)
Changes in working capital:    
Decrease (increase) in amounts receivable (3,246) 733,629
Decrease (increase) in prepaid expenses 961,118 492,279
(Decrease) increase in accounts payable 3,710,836 (3,887,078)
Increase (decrease) in accrued expenses and other payables 292,824 753,909
Net cash used in operating activities (28,651,323) (28,170,520)
Cash flow from investing activities:    
Purchase of property and equipment (127,049)
Purchase of short-term investments, net (24,590,000) (7,316,000)
Proceeds from short-term investments 21,289,000
Equity investment in BC Therapeutics (377,000) (330,000)
Net cash used in investing activities (3,805,049) (7,646,000)
Cash flow from financing activities:    
Proceeds from exercise of warrants 821,015
Proceeds from issuance of shares, net of issuance costs ($2,894,567 and $6,277,240, respectively) 31,814,999 44,627,224
Net cash provided by financing activities 31,814,999 45,448,239
Increase (decrease) in cash and cash equivalents (641,373) 9,631,719
Cash and cash equivalents at beginning of year 10,493,808 862,089
Cash and cash equivalents at end of year $ 9,852,435 $ 10,493,808